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Abstract
Background: Temporomandibular joint (TMJ) arthritis in children causes alterations in the craniomandibular growth.
Resultant abnormalities include; condylar erosions, a posterior mandibular rotation pattern, micrognathia, malocclusion
with an anterior open bite, altered joint and muscular function occasionally associated with pain. These alterations may
be prevented by early aggressive anti-inflammatory intervention. Previously, we have shown that intra-articular (IA)
corticosteroid reduces TMJ inflammation but causes additional mandibular growth inhibition in young rabbits. Local
blockage of TNF-α may be an alternative treatment approach against TMJ involvement in juvenile idiopathic arthritis (JIA).
We evaluated the anti-inflammatory effect of IA etanercept compared to subcutaneous etanercept in antigen-induced
TMJ-arthritis in young rabbits in terms of mandibular growth. This article (Part II) presents the data and discussion on
the effects on facial growth. In Part I the anti-inflammatory effects of systemic and IA etanercept administration are
discussed.
Methods: Arthritis was induced and maintained in the TMJs of 10-week old pre-sensitized rabbits (n = 42) by four
repeated IA TMJ injections with ovalbumin, over a 12-week period. One group was treated weekly with systemic
etanercept (0.8 mg/kg) (n = 14), another group (n = 14) received IA etanercept (0.1 mg/kg) bilaterally one week after
induction of arthritis and one group (n = 14) served as an untreated arthritis group receiving IA TMJ saline injections.
Head computerized tomographic scans were done before arthritis was induced and at the end of the study. Three small
tantalum implants were inserted into the mandible, serving as stable landmarks for the super-impositions. Nineteen
variables were evaluated in a mandibular growth analysis for inter-group differences. All data was evaluated blindedly.
ANOVA and T-tests were applied for statistical evaluation using p < 0.05 as significance level.
Results: Significant larger mandibular growth disturbances were observed in the group receiving IA saline injections
compared with the systemic etanercept group. The most pronounced unfavourable posterior mandibular rotation
pattern was observed in the group receiving IA saline injections.
Conclusion: Intervention with systemic etanercept monotherapy equivalent to the recommended human dose allows
a mandibular growth towards an original morphology in experimental TMJ arthritis. Systemic administrations of
etanercept are superior to IA TMJ administration of etanercept in maintaining mandibular vertical growth.
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Background
Temporomandibular joint (TMJ) arthritis in growing indi-
viduals severely affects the endochondral ossification in
the condylar cartilage responsible for a substantial part of
the mandibular growth [1,2]. The intracapsular location
of this growth cartilage is a unique characteristic of the
TMJ and it makes this joint vulnerable to inflammatory
changes. It is evident that the pronounced mandibular
growth deviations seen in juvenile idiopathic arthritis
(JIA) patients is a consequence of TMJ arthritis [3-5].
Resultant abnormalities include; condylar deformities,
reduced vertical mandibular ramus growth, a critical pos-
terior clockwise mandibular rotation pattern and reduced
muscular and TMJ function, occasionally associated with
pain, and a secondary affection of the maxilla and soft tis-
sue [3-6]. JIA patients with TMJ involvements are mainly
treated with orthopaedic procedures and corrective sur-
gery after mandibular growth disturbances have occurred
[7,8]. These treatment modalities are long of duration,
comprehensive and require excellent patient cooperation.
We hypothesize that early aggressive intervention against
TMJ arthritis aimed against the inflammatory process per
se would be advantageous and allow mandibular growth
towards an original morphology. Beneficial symptomatic
and functional improvements of intra-articular (IA) corti-
costeroid injections for the treatment of TMJ arthritis in
children with JIA have been described [9-11]. However,
these studies do not address the potential negative long-
term effects of IA TMJ corticosteroid injections on condy-
lar cartilage and craniofacial growth. This calls for atten-
tion since long-term side-effects on mandibular growth
may outweigh the beneficial short-term effects. Previ-
ously, we have published data to support that, despite of
significant inflammatory reduction, IA TMJ corticosteroid
injections seem to have unfavourable effects on the man-
dibular growth in experimental studies [12,13]. As always,
it requires caution and careful consideration when apply-
ing the findings in an experimental TMJ arthritis model to
humans but our previous findings warrant the search for
alternative local anti-inflammatory treatment procedures.
TNF-α plays an important role in the pathogenesis of JIA,
and high levels of TNF-α are associated with a negative
effect on the endochondral ossification [14-17]. Addition-
ally, in rheumatoid arthritis (RA) TMJ pain and tissue
destruction are associated with elevated synovial levels of
TNF-α [18,19]. In polyarticular JIA not responding to
standard DMARD therapy with methotrexate, the efficacy
and safety of etanercept given subcutaneously have been
well documented [20]. In RA patients IA etanercept has
shown a good response in terms of symptomatic relief
[21,22]. No previous study has addressed the topic of
mandibular growth and anti-TNF-α therapy against TMJ
arthritis.
In the present study we investigated the effect of systemic
and IA administration of etanercept on mandibular
growth in experimental antigen-induced TMJ arthritis in
rabbits. We hypothesized that the anti-inflammatory
treatment with TNF-α blockers would allow a mandibular
growth towards an original morphology in antigen-
induced TMJ arthritis compared to an IA saline treated
group. The anti-inflammatory effects of the etanercept
interventions are described in part I: Histological Effects
[23].
Methods
Ten-week old female New Zealand white rabbits (n = 42)
(Oryctolagus cuniculus) were housed at the animal facilities
of the University of Aarhus, Denmark, with free access to
water and food. Animal welfare was monitored by daily
evaluation of food and water intake. Prior to arrival the
animals were randomly divided into three groups by
block randomisation; a) IA TMJ saline group, n = 14 (0.1
ml pr. joint), b) IA TMJ etanercept group, n = 14 (0.1 mg/
kg pr. joint), c) systemic etanercept group, n = 14 (0.8 mg/
kg subcutanously). All animals had TMJ arthritis induced
as described in Part I [23] (figure 1).
Prior to T1 all animals had three 1.0 × 0.33 mm tantalum
implants inserted in the mandible serving as stable land-
marks used in the mandibular growth analysis [1,24].
One implant was inserted close to the mandibular symph-
ysis and another in the molar region in both sides of the
mandible. Two sets of full head CT scans (Phillips/
Mx8000 IDT 16) were taken at T1 and at T2 (age 26
weeks); resulting in a growth period of 12 weeks. All ani-
mals were sacrificed at age 26 weeks. Implant operation,
TMJ injections and euthanization were carried out under
general anaesthesia and all procedures were approved by
the Danish Ethical Committee for animal welfare. IA
injections and surgical procedures were carried out in a
blinded fashion by trained specialists.
Growth variables
Evaluation of inter-group growth differences between T1
and T2 were evaluated by a mandibular growth analysis
based on CT scans. Figure 2 shows the anatomical land-
marks and implants used for definition of the variables
evaluated. Figures 3, 4 and 5 show the 19 variables evalu-
ated at T1 and T2 used in the analysis of mandibular mor-
phology changes in each animal. Variables describing
vertical and sagittal changes were obtained from the right
side of the animals.
The scanned images were digitised by one author (PS)
using the image evaluation software program Mimics
(Mimics 11, Materialise, Leuven, Belgium) and all images
were assessed in a blinded fashion before group assign-
ment was revealed. Only statistical analyses prespecifiedPediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
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in the investigation protocol were performed. The data
were statistically processed using the software program
Stata (Intercooled Stata 8.2, StataCorp, Texas, USA).
Statistics
All continuing variables were evaluated for normal distri-
bution. At T1, absolute inter-group differences for each of
the nineteen variables were evaluated by one-way
ANOVA-tests. Sagittal, vertical and transverse intra-group
growth between T1 and T2 were evaluated by paired t-
tests. In each of the nineteen variables differences in the
relative inter-group growth between T1 and T2 were eval-
uated using one-way ANOVA-tests. Student's t-tests were
applied as post-ANOVA tests in variables when signifi-
cance was found in the ANOVA-tests. The necessity for a
Bonferroni correction for avoidance of mass significance
in the post-ANOVA inter-group Student's t-tests was dis-
cussed. However, to avoid type-2 errors due to the corre-
lation between the nineteen variables evaluated in each
animal, this correction was found too strong and not
implemented in the statistical analysis. In a previous
study, acceptable intra-observer variance and inter-scan
accuracy were demonstrated using the same measuring
methods, equipment and observer as in this study [13].
Power calculations were performed at T2 in order to eval-
uate the validity of our findings in relation to the number
of animals completing the study. The parameters for the
calculations were 2α = 0.05 and β = 20. Discussed below
are only findings sufficiently powered. The level of signif-
icance used was p < 0.05.
Results
Thirty-two animals completed the study. The distribution
of the completers at T2 were; nine from the IA saline
group, ten from the IA etanercept group and thirteen from
the systemic etanercept group. One animal from the sys-
temic etanercept group was excluded from the final
growth analysis due to abnormal histological TMJ find-
ings in this animal [23].
At T1 mandibular maturation was identical for all three
study groups. This was confirmed by no absolute inter-
group differences in any of the nineteen cephalometric
variables at T1 (Table 1). Significant sagittal, vertical and
transverse intra-group growth in almost all of the three
groups was observed during the 12 weeks of growth (p <
0.05). An exception for this was the growth of the dentoal-
veolar height (DAH) in the IA etanercept group which did
not demonstrate growth between T1 and T2. This is
explained by the small growth increment and the large
Flow chart illustrating the study design Figure 1
Flow chart illustrating the study design.
Rabbits n=42
Pre-sensitization, age 10 → 14 weeks
Randomization
IA
Saline
n=14
IA
etanercept
n=14
Systemic
etanercept
n=14
Induction of arthritis bilaterally in the TMJs
I.a. saline in 
TMJs
Systemic 
etanercept
I.a. etanercept
in TMJs
T2: Second head CT-scan session and euthanization, age 26 weeks 
5† 4† 1† + 1 outlier
Repeated 
x 4 with 
3-week 
interval
Weekly from
age 15 weeks
One week
T1: First head CT-scan session, age 14 weeksPediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
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variation in the growth of this variable. The implant A to
implant B distances did not change between T1 and T2.
This documents the stable properties of the implants
inserted. Between T1 and T2 angle 1 did not open signifi-
cantly in any of the groups; Angle 2 closed significantly
only in the IA saline group and Angle 3, signifying the
angle between the ramus and the horizontal plane of the
mandible, opened significantly in all three groups.
Anatomical landmarks Figure 2
Anatomical landmarks. Cm (Condylar midpoint), Ar1 
(Articulare 1), Ar2 (Articulare 2), Go (Gonion), Ba (Basion 
point), Inc (Incisal point), Mol (Molar point). The implant 
points were located on the right side: ImpA (Implant A) and 
ImpB (Implant B). The following two lines were defined: ML 
(Mandibular line) from Go to Ba, defined at the right side; IL 
(Implant line) going through ImpA-ImpB. For specific defini-
tions of the anatomical landmarks see Stoustrup et al. 2008 
[12].
Angles and transverse variables measured Figure 3
Angles and transverse variables measured. Angle1: 
Cm-ImpA-ImpB; Angle2: Go-ImpA-ImpB; Angle3: Cm-Go-
Ba; Condylar distance (CD): Cmright-Cmleft; Gonial dis-
tance (GD): Goright-Goleft.
Vertical variables measured Figure 4
Vertical variables measured. Total posterior mandi-
ble height (TPMH): Cm-Go; Collum mandibular height 
1 (CMH1): Cm-Ar1; Collum mandibular height 2 
(CMH2): Cm-Ar2; Ramus height 1 (RH1): Ar1-Go; 
Ramus height 2 (RH2): Ar2-Go; Mandibular body 
height 1 (MBH1) Inc ⊥ IL; Mandibular body height 2 
(MBH2): Mol ⊥ ML; Dentoalveolar height (DAH): Mol ⊥ 
IL; Height of angular notch (ANH): Inc ⊥ ML.
Sagittal variables measured Figure 5
Sagittal variables measured. Mandibular length 1 
(ML1) Go-ImpB; Mandibular length 2 (ML2) Ar1-ImpB; 
Mandibular length 3 (ML3) Ar2-ImpB; Total mandibular 
length (TML) Cm-ImpB; Implant distance (ID): ImpA-
ImpB. Figures from Stoustrup et al. 2008 [12].Pediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
Page 5 of 9
(page number not for citation purposes)
Evaluation of relative inter-group differences in mandibu-
lar growth during the 12 weeks of growth observed we
found no significant differences in terms of angular, sagit-
tal and transverse mandibular maturation and growth. In
the vertical dimension a significant relative inter-group
difference in mandibular growth was observed in the total
posterior mandibular height (TPMH) (p < 0.05). Post-
ANOVA tests showed that the relative growth of the total
posterior mandibular height (TPMH) was significantly
larger in the systemic etanercept group (p < 0.05), but not
for the IA etanercept group, compared with the IA saline
group of animals (figure 6). A non-significant trend (p <
0.1) towards a difference in the relative growth of the
TPMH was observed between the systemic etanercept
group and the IA etanercept group. In variables such as the
mandibular body height 1 (MBH1) and the antegonial
notching height (ANH) large inter-group differences in
the relative growth were observed but due to the combina-
tion of large variations and a small growth in these varia-
bles no significant differences were observed.
Discussion
In this study we have demonstrated that subcutaneous
etanercept administration, in a weekly dose of 0.8 mg/kg,
allows a mandibular growth towards an original mor-
phology. Additionally, we found that systemic etanercept
is superior to IA etanercept administration (0.1 mg/kg at
times of inflammatory flares) in supporting mandibular
vertical growth. In terms of mandibular rotational growth,
all three experimental groups demonstrated an unfavour-
able posterior clockwise mandibular rotation pattern
illustrated by an opening of the mandibular angle (Angle
3) (figure 7). However, most critical posterior rotation
pattern was observed in the IA saline group in which a
closing of Angle 2 occurred additionally. Reduced vertical
mandibular growth and mandibular posterior rotation
are two of the most pronounced and critical clinical fea-
tures in JIA patients with inflammatory TMJ changes [3,5].
Both of these features are signs of very unfavourable man-
dibular growth [1,24].
The findings in this study indicate that the mandibular
growth is most efficiently supported by a weekly systemic
anti-inflammatory and immunomodulatory therapy
compared to a local anti-inflammatory therapy at times of
inflammatory flares. However, there are several possible
reasons for the lack of effect of IA etanercept in this study
that need further attention. It is not known how long IA
administered etanercept stays in the joint before being
absorbed and entering circulation: etanercept has an elim-
ination half life between 70.8 and 96.4 hours [25].
Despite of an expected higher concentration of TNF-α
inhibitor within the TMJs, achieved by IA injections com-
pared to systemic etanercept administration, the duration
of IA injected etanercept seems to have an insufficient
clinical effect on the TMJ arthritis to result in beneficial
long-term results on mandibular growth. The concentra-
tion of the IA etanercept injected could therefore have
been insufficient. The dose of the systemically adminis-
tered etanercept (0.8 mg/kg subcutaneously) used in this
study is in agreement with the recommended weekly dose
of etanercept in humans [20]. This dose is not equivalent
to the dose of IA etanercept administered and this may
explane our findings. At the beginning of this study the IA
etanercept concentration used (0.1 mg/kg) was decided
based on the sparse information published on IA etaner-
cept in letters and case reports. After initiating our study,
Bliddal et al. described good symptomatic and functional
results by the use of IA etanercept injections in RA patients
(wrist, knee or elbow) with injections of 0.3 mg/kg etaner-
cept (25 mg/joint) [22].
Aspects to consider in future studies are whether to give IA
injections more frequently than at times of flares, increase
the IA injected etanercept concentration, use another TNF-
α inhibitor with a prolonged elimination, or to see if the
effect of IA etanercept injections would have been
improved when supported by another anti-inflammatory
or immunomodulatory systemically administered ther-
apy. Recently, repeated IA infliximab (Remicade®, Cento-
cor) injections in the TMJ in RA patients have been
described with good results [26].
In the present study, the IA saline group and IA etanercept
group animals received more TMJ injections per animal
than the systemic etanercept group animals. Histologi-
cally, we have shown that IA TMJ saline injections per se
do not result in any inflammatory or destructive changes
in the joint [12]. Therefore, the fact that the number of
TMJ injections per joint per se being lower in the systemic
etanercept group does not seem to be of crucial impor-
tance for the influence on mandibular growth.
It requires special caution and careful consideration when
applying findings in experimental studies to humans. In
this study we used etanercept (a humanized TNF-α recep-
tor fusion protein) for the treatment of inflammation in
rabbits. However, etanercept has a documented effect on
rabbit inflammation as described in Part I of this study
[23]. Additionally, non-pathological rabbit mandibular
growth resembles non-pathological human mandibular
growth [27]. The experimental arthritis model used in this
study is well described [28]. It shows similar mandibular
growth deviations in rabbits compared to the pathologi-
cally mandibular growth deviations seen in JIA children
with inflammatory TMJ changes [29].
In rabbits approximately 90% of the overall mandibular
growth is achieved before the sixteenth week and has
almost ceased at age 26 weeks [30]. Yet, launching thisPediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
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Table 1: Absolute intra-group differences between T1 (week 14) and T2 (week 26) together with mean relative difference for each of 
the variables in each group evaluated.
Variable Group Absolute mean 
T1 value
Absolute mean 
T2 value
Absolute mean 
difference T2-T1
Relative mean 
difference from T1 
to T2 (%)
Standard 
deviation (%)
Statistical significance 
for growth between 
T1 and T2
Angle 1 A 155.3 156.6 1.3 0.84 1.7 n.s.
B 155.8 156.4 0.6 0.4 2.9 n.s.
C 153.9 154.1 0.2 0.1 1.6 n.s.
Angle 2 A 136.1 133.8 -2.3 -1.7 2.2 *
B 136.2 135.1 -1.1 -0.7 5.2 n.s.
C 138.7 137.4 -1.3 -1 2.2 n.s.
Angle 3 A 108.3 109.3 1 0.9 1.2 *
B 107.3 108.6 1.3 1.3 1.5 *
C 108.3 109.6 1.3 1.2 1.3 *
Sagittal (mm)
TML A 61.5 66.6 5.1 8.3 2.1 *
(Cm-ImpB) B 60.7 65.8 5.1 8.4 1.9 *
C 60.8 66.2 5.4 8.8 1.8 *
ML1 A 36.2 38.1 1.9 5 2.4 *
(Go-ImpB) B 36.5 38.2 1.7 4.6 2.5 *
C 35.9 37.6 2 5 2.1 *
ML2 A 55.6 59.7 4.1 7.3 1.7 *
(Ar1-ImpB) B 55.3 59.0 3.7 7.2 2.2 *
C 54.8 58.7 3.9 7.2 2.6 *
ML3 A 58.6 63.3 4.7 8 1.8 *
(Ar2-ImpB) B 58.6 63.1 4.5 7.7 0.9 *
C 58.3 62.8 4.5 7.7 1.4 *
ID A 15.1 15.5 0.4 3 6.2 n.s.
(impA-impB) B 14.8 15.1 0.3 2.7 5.8 n.s.
C 14.1 14.0 -0.1 -1.3 8.1 n.s.
Vertical (mm)
TPMH A 44.2 48.8 4.6 10.4 1.5 *
(CmR-GoR) B 43.3 47.9 4.6 10.8 1.9 *
C 43.5 49.0 5.5 12.6 1.7 *
CMH1 A 21.4 23.7 2.3 10.7 1.1 *
(CmR-Ar1) B 21.1 23.2 2.1 9.9 3.5 *
C 21.3 23.6 2.3 10.8 2.6 *
CMH2 A 22.3 24.3 2 8.9 2.0 *
(CmR-Ar2) B 22.2 24.3 2.1 9.4 2.9 *
C 22.1 24.4 3.3 10.0 2.3 *
RH1 A 27.4 30.3 2.9 10.7 2.5 *
(Ar1-GoR) B 26.8 29.7 2.9 11.0 2.3 *
C 26.8 29.9 3.1 11.6 3.5 *
RH2 A 29.5 32.9 3.4 11.9 3.4 *
(Ar2-GoR) B 28.9 32.5 3.6 12.3 2.5 *
C 29.2 32.9 3.7 12.7 2.7 *
MBH1 A 12.5 13.8 1.3 10.4 13.9 *
(IncR IL) B 12.7 13.4 0.7 6.91 16.3 *
C 12.3 13.6 1.3 12.1 12.4 *
MBH2 A 18.3 20.5 2.2 12.2 3.7 *
(MolR IL) B 17.9 19.8 1.9 11.1 2.9 *
C 17.7 20.2 2.5 14.1 3.9 *
DAH A 7.5 8.2 0.7 8.9 10.6 *
(MolR ML) B 7.3 7.9 0.6 8.8 14.4 n.s.
C 7.7 8.7 1 12.6 8.4 *
ANH A 2.9 3.4 0.5 17.2 18.2 *
(IncR ML) B 2.9 3.4 0.5 17.2 26.9 *Pediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
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study at an earlier animal age was not possible due to
Danish legislation on animal welfare. Systemic presensiti-
zation with antigen was initiated in age 10 weeks and the
first IA TMJ antigen injections were introduced at age 14
weeks. In rabbits the greatest mandibular growth acceler-
ation is seen in the early postnatal period and reduces at
age 14 weeks [30], so obviously it would have been pref-
erable to initiate this trial in younger animals. In this
study, the significant inter-group differences in mandibu-
lar vertical growth occur within the final 10–15% of the
overall mandibular growth. Therefore, we hypothesize
that greater inter-group differences in several mandibular
growth variables could have been revealed if the trial was
initiated in younger animals during the growth accelera-
tion because of an increased mandibular growth potential
left. This may explain the lack of differences on angular,
sagittal and transverse measurements. Ten animals did
not complete the full length of the study and it is ques-
tionable whether TMJ arthritis induction could have been
initiated at an earlier animal age without extensive loss of
animals. All animals lost in the experimental phase were
lost due to anaphylactic shock right after the IA TMJ anti-
C 2.6 2.9 0.3 11.5 35.3 *
Transverse (mm)
GD A 28.1 29.6 1.5 5.5 2.8 *
(GoR-GoL) B 29.0 30.1 1.1 3.9 2.0 *
C 28.4 29.9 1.5 5.5 2.5 *
CD A 33.4 34.7 1.3 4.3 2.4 *
(CmR-CmL) B 32.5 33.9 1.4 4.5 2.2 *
C 33.2 34.4 1.2 3.7 1.3 *
*P < 0.05
Angles (degrees)
Groups: A) placebo, B) IA etanercept, C) systemic etanercept. See figures 3, 4 and 5 for a description of the variables.
Table 1: Absolute intra-group differences between T1 (week 14) and T2 (week 26) together with mean relative difference for each of 
the variables in each group evaluated. (Continued)
The relative growth of the total posterior mandibular height  (TPMH) Figure 6
The relative growth of the total posterior mandibu-
lar height (TPMH). The growth of this variable was signifi-
cantly larger (p < 0.05) in the systemic etanercept group 
(TPMH 12.6% [CI-95: 11.0–13.1]) compared with the IA 
saline group (TPMH 10.4% [CI-95: 9.2–11.5]). A non-signifi-
cant trend (p < 0.1) towards a difference in the relative 
TPMH growth was observed between the systemic etaner-
cept group (TPMH 12.6% [CI-95: 11.0–13.1]) and the IA 
etanercept group (TPMH 10.8% [CI-95: 9.2–12.2]).
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The findings of this study Figure 7
The findings of this study. Intervention with systemic 
etanercept monotherapy equivalent to the recommended 
human dose allows mandibular growth towards an original 
morphology by significantly improved growth of the total 
posterior mandibular height (see TPMH variable at small 
arrow). Systemic etanercept (0.8 mg/kg weekly) administra-
tion is superior to IA TMJ etanercept administration at times 
of inflammatory flares in maintaining mandibular vertical 
growth. All three groups demonstrated an unfavourable 
clockwise posterior mandibular rotation pattern, illustrated 
by an opening of Angle 3 (large arrow). The most pro-
nounced posterior mandibular rotation was observed in the 
IA saline group in which a closing of Angle 2 also occurred.Pediatric Rheumatology 2009, 7:6 http://www.ped-rheum.com/content/7/1/6
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gen injections. The majority of lost animals died during
the first two antigen challenge procedures.
The orthopaedic treatment of JIA patients with TMJ
inflammation is long of duration, comprehensive and
requires good patient cooperation. Often the clinical signs
of TMJ arthritis are vague and the disorder is often over-
looked [6]. Early aggressive intervention against TMJ
involvement aimed against the inflammatory process per
se could allow mandibular growth towards an original
morphology. Symptomatic and functional improvements
of IA corticosteroid injections for the treatment of TMJ
arthritis in children have been described [9,11]. However,
previously we have published data supporting that,
despite of significant inflammatory reduction, these injec-
tions have a highly unfavourable effect on the mandibular
growth in experimental studies [12,13]. Therefore,
searches for alternative local anti-inflammatory treat-
ments are warranted in the future. This study suggests that
early intervention with systemic etanercept monotherapy
weekly is beneficial and allows growth towards an origi-
nal morphology. It could be of great clinical interest to
consider the effect of systemic etanercept as a compliment
to an orthopaedic mandibular correction with orthodon-
tic splint therapy in the intervention against early mandib-
ular growth alteration in JIA patients. Another interesting
clinical aspect is if a synergistic effect on mandibular
growth can be achieved with a combination of methotrex-
ate and systemic anti-TNF-α administration. Data have
documented that monotherapy with methotrexate
reduces TMJ destruction and growth alterations and
craniofacial dysmorphology in polyarticular JIA children
with TMJ arthritis [31]. In RA patients a synergistic good
therapeutic effect on structural joint damage has been
described when methotrexate and systemic anti-TNF-α
therapy have been combined [32].
Conclusion
Treatment of experimental TMJ arthritis with systemic
etanercept monotherapy weekly, equivalent to the recom-
mended human dose, allows mandibular growth towards
an original morphology which is unlike our previous
findings with IA corticosteroids for the treatment of exper-
imental TMJ arthritis. Weekly systemic etanercept admin-
istrations are superior to IA TMJ etanercept
administration, at times of antigen induced inflammatory
flares, in maintaining mandibular vertical growth.
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